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Abstract
Clinical benefit of invasive functionally guided revascularization has been mostly investigated and proven for percutaneous
coronary intervention. It has never been prospectively evaluated whether a systematic fractional flow reserve (FFR) assessment
is also beneficial in guiding coronary artery bypass graft surgery (CABG). The objective of the GRAft patency after FFR-guided
versus angiography-guIded CABG (GRAFFITI) trial was to compare an FFR-guided revascularization strategy to the traditional
angiography-guided revascularization strategy for patients undergoing CABG. Patients were enrolledwith significantly diseased left
anterior descending or left main stem and at least one major coronary artery with angiographically intermediate stenosis (30–90%
diameter stenosis) that was assessed by FFR. Thereafter, while the FFR values were kept concealed, cardiac surgeons decided their
intended procedural strategy based on the coronary angiography alone. At this point, patients underwent 1:1 randomization to either
an FFR-guided or an angiography-guided CABG strategy. In case the patient was randomized to angiography-guided arm, cardiac
surgeons kept their intended procedural strategy, i.e., CABGwas guided solely on the basis of the coronary angiography. In case the
patient was randomized to the FFR-guided arm, FFR values were disclosed to the surgeons who revised the surgical protocol
according to the functional significance of each coronary stenosis. The primary endpoint of the trial was the rate of graft occlusion at
12 months, assessed by coronary computed tomography or coronary angiography. The secondary endpoints were (1) length of
postoperative hospital stay; (2) changes in surgical strategy depending upon FFR results (in FFR-guided group only); and (3) rate of
major adverse cardiac and cerebrovascular events, i.e., composite of death, myocardial infarction, stroke, and any revascularization
during the follow-up period. This study is the first prospective randomized trial investigating potential clinical benefits, associated
with FFR-guided surgical revascularization. Trial registration: NCT01810224
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Abbreviations
CABG Coronary artery bypass graft surgery
CAD Coronary artery disease
CCTA Coronary computed tomography angiography
FFR Fractional flow reserve
LAD Left anterior descending coronary artery
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Introduction
Several large registries have proven major discrepancy between
the angiographic appearance and the functional importance of
coronary stenoses, limiting the appropriate therapeutic decision-
making when purely assessed by angiography [1–3].
Accordingly, the latest joined guidelines of the European
Society of Cardiology and European Association of Cardio-
Thoracic Surgery [4, 5] on myocardial revascularization under-
score the importance thatmyocardial revascularization in patients
with stable coronary artery disease (CAD) should be justified
with demonstrated significant myocardial ischemia.
Consistently, revascularization of angiographically equivocal
coronary stenoses should be limited to lesions responsible for
reversible ischemia based on invasive fractional flow reserve
(FFR) assessment. This recommendation is supported by the fact
that percutaneous coronary intervention (PCI) of all and
exclusively the lesions with FFR ≤ 0.80 results into an improved
clinical outcome overcoming the traditional way to assess the
stenosis severity basedmainly upon coronary angiography [6, 7].
However, it has never been prospectively evaluated wheth-
er a systematic FFR assessment is also beneficial as compared
to the traditional angiographic evaluation in guiding coronary
artery bypass graft surgery (CABG). The available data are in
fact coming either from retrospective or from single-arm pro-
spective registries. Botman et al. [8] found a significant rela-
tion between functional severity of CAD determined by FFR
and graft patency at 1 year. Similarly, in a retrospective regis-
try, when comparing FFR-guided and angiography-guided
CABG, a significantly higher graft patency rate was observed
in the FFR-guided group. However, no significant difference
was observed in terms of major adverse clinical endpoints at
3 years [9]. These preliminary data advocated the need for a
randomized clinical trial prospectively evaluating the potential
benefit of FFR-guided over angiography-guided CABG.
The objective of the GRAft patency after FFR-guided versus
angiography-guIded CABG (GRAFFITI) trial was to assess the
importance of functional assessment of CADprior to CABG. In
particular, an FFR-guided strategy was compared to the tradi-
tional angiography-guided strategy in the procedural planning
and performance of surgical revascularization. Based on previ-
ous data [8], we hypothesized that rate of graft patency in the
case of FFR-guided bypass surgery is significantly higher at 1-
year follow-up, than in the case of angiography-guided bypass
surgery. We also presumed that FFR-guidance might be bene-
ficial in terms of recovery and length of hospitalization, mainly
through a reduction in the need of more extensive surgical
intervention (i.e., reduced number of grafts needed; reduced
rate of on-pump surgical approach)[9].
Methods
Patient Population
FromMarch 2012 to December 2016, all consecutive patients
undergoing elective coronary angiography for stable angina,
unstable angina or non-STelevation acute coronary syndrome
were screened for possible inclusion in the presence of (1)
significant stenosis of the left main stem (LM) and/or the left
anterior descending coronary artery (LAD) proven by angiog-
raphy or by FFR (≤ 0.80) and (2) at least one other major
coronary artery with a lesion of diameter stenosis between
30 and 90% by visual assessment [4, 5] in any of the other
coronary arteries.
Patients were excluded in case of (1) acute ST elevation
myocardial infarction; (2) moderate to severe valve disease
with indication for valve surgery; (3) severe left ventricular
dysfunction (ejection fraction < 35%); and (4) atrial fibrilla-
tion, if MAZE procedure was considered.
As of March 2012, recruitment was slow with about 160
patients enrolled by December 2016; therefore, steering com-
mittee decided for closing enrollment.
Study Design
The GRAFFITI trial is designed as a single-blinded, open-
label, prospective 1:1 randomized controlled multi-center tri-
al, conducted in the following 6 European centers: the
Cardiovascular Research Center Aalst—OLV Hospital
(Aalst, Belgium), the University of Verona (Verona, Italy),
the University Hospital of Brno (Brno, Czech Republic), the
Hospital Santa of Marta (Lisbon, Portugal), the Hungarian
Institute of Cardiology (Budapest, Hungary), and the Na
Homolce Hospital (Prague, Czech Republic). The trial is reg-
istered on www.clinicaltrials.gov (NCT01810224).
The study design is summarized in Fig. 1. Briefly, the study
was designed to compare angiography-guided with FFR-
guided revascularization in patients undergoing coronary ar-
tery bypass surgery, based on significant LM or LAD disease
[4, 5]. Patients were enrolled after having signed the written
informed consent and if they meet all the eligibility criteria,
namely having a significantly diseased LAD or LM (by angi-
ography or by FFR) and at least one more major coronary
artery with an angiographically intermediate stenosis (30–
90% diameter stenosis).
After enrollment, FFR was measured during the same pro-
cedure in all intermediate stenoses. Note that the FFR values
were concealed and the cardiologist involved in the procedure
did not participate further to discuss on the revascularization
strategy for the patient. Thereafter, patients were discussed
within the heart team and cardiac surgeons defined their
intended surgical revascularization strategy based on the cor-
onary angiography alone, blinded to the FFR values. In
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particular, they identified the number and type of grafts, the
number of anastomoses and the surgical technique. The con-
sensus on the surgical strategy was recorded in the case report
form. At this point, patients underwent 1:1 randomization to
either an FFR-guided or an angiography-guided CABG strat-
egy. Randomization was done by a web-based platform. In
case the patient was randomized to angiography-guided arm,
FFR values remained concealed and cardiac surgeons per-
formed the intended CABG strategy according to what pre-
defined on the angiogram. In case the patient was randomized
to the FFR-guided arm, measured FFR values were disclosed
to the surgeons who were mandated to readjust the surgical
protocol according to the functional significance of each cor-
onary stenoses, regardless of the angiographic appearance,
i.e., stenoses with FFR ≤ 0.80 were grafted, while stenoses
with FFR > 0.80 were left alone. Changes in the revasculari-
zation strategies based upon functional information as com-
pared with the initially intended strategy were recorded.
Endpoints
The primary endpoint of the trial was the rate of graft occlu-
sion at 12 months. For evaluation, coronary computed tomog-
raphy angiography (CCTA) was favored, considering its reli-
ability in detecting graft patency [10]. Assessment was done
by two experienced cardiologists (CVM, MP), blinded to ran-
domization. All grafts were considered as patent or occluded.
In case of clinically indicated coronary angiography, graft pa-
tency was assessed during the angiographic examination ac-
cording to good clinical practice. In the latter case, CCTAwas
not performed.
The secondary endpoints were (1) length of postoperative
hospital stay; (2) changes in surgical strategy depending upon
FFR results (in FFR-guided group only), i.e., open-chest sur-
gery vs. mini-thoracotomy; on-pump vs. off-pump; and num-
ber of grafts and anastomoses; and (3) rate of major adverse
cardiac and cerebrovascular events, i.e., composite of death,
myocardial infarction and stroke, and any revascularization
during the follow-up period.
Statistics
Based on the limited data in the literature [8, 9], we assumed
an absolute difference of 10% in the rate of occluded graft at
1 year between the two groups. Therefore, we calculated a
sample size of 206 patients with 80% power, an alpha of
0.05, and a 20% lost to follow-up.
Continuous variables will be compared by unpaired
Student’s t tests, Mann-Whitney tests, or ANOVA test and
categorical variables will be compared with Fisher’s exact or
Fig. 1 GRAft patency after FFR-
guided versus angiography-
guIded CABG TrIal (GRAFFITI)
(LAD, left anterior descending
coronary artery; LM, left main
stem; FFR, fractional flow re-
serve; DS, diameter stenosis;
CCTA, coronary computed to-
mography angiography; CA, cor-
onary angiography)
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chi-square tests, as appropriate. The difference in survival will
be calculated by applying the Kaplan-Meier curves. Results
will be adjusted by Cox-regression multivariate analysis, as
appropriate. A probability value of p < 0.05 is considered as
significant.
Discussion
While there are already strong data supporting functionally
guided percutaneous revascularization, data on functionally
guided surgical revascularization is still limited in the litera-
ture. Accordingly, coronary artery bypass surgery is still fol-
lowing mainly the traditional way of angiogram-based
revascularization.
Existing data so far are derived from observational studies
and they seem to support the prognostic role of FFR in pa-
tients with planned CABG in terms of complexity of surgery,
graft patency, etc. [11]. Still, since data from a prospective
randomized clinical trial are still missing to confirm the con-
cept, that FFR might play an important role in risk stratifica-
tion and determining management strategy for these patients.
GRAFFITI trial is the first of its kind evaluating the use of
FFR-guidance for patient assessment prior CABG. This study
will provide novel insight on the potential impact of invasive
functional guidance of CABG on surgical strategy, number of
clinically indicated grafts and their long-term patency.
Based on a robust wealth of data, proving the clinical ben-
efit of FFR-guided revascularization, the traditional anatomy-
based revascularization paradigm has been already shifted to-
wards a more functionality-centered concept in the PCI field
[4–7, 12, 13]. However, surgical revascularization is still
mainly following the angiographic paradigm. This study
might be the first prospective randomized trial, investigating
potential clinical benefits, associated with FFR-guided surgi-
cal revascularization. Accordingly, results of the study might
allow understanding, whether the same paradigm-shift is
needed in surgical revascularization, as well.
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